Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 16;48(21):12135–12150. doi: 10.1093/nar/gkaa1051

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 5. — Deletion of the enhancer inhibits tumorigenesis in vitro and in vivo. (A) KEGG analysis showing tumor cell growth after enhancer deletion. X axe: Gene ratio (number of counts/total genes); Y axe: Altered signaling pathways, tumorigenesis related pathways were shown in the data. The size of dot represents gene counts and the color represent P value. (B) Plate clone formation assay demonstrated that tumor formation ability was significantly reduced in enhancer-deleted OCM1 cells. (C) Suppressive effects on tumor volume in enhancer-deleted OCM1 cells in a subcutaneous xenograft model. Data are presented as the mean ± SD and the differences between two groups were calculated by unpaired two-tailed Student's t-test. * P < 0.05, ** P < 0.01. (D, E) Animal imaging system demonstrated the suppressive effects on tumor bioluminescent signals in enhancer-deleted OCM1 cells in orthotopic xenografts. (F) Suppressive effects on weight in enhancer-deleted OCM1 cells in orthotopic xenografts. Data are presented as the mean ± SD and the differences between two groups were calculated by unpaired two-tailed Student's t-test. * P < 0.05, ** P < 0.01. (G) Prolonged survival time in enhancer-deleted OCM1 cells in orthotopic xenografts. (H) Fewer metastatic spots in enhancer-deleted OCM1 cells in the metastatic model.